SOHO 2023 Annual Meeting-Hybrid
Sep 6-9, 2023

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.

Content to be used in accordance with local CPO guidelines

List of Presentations

ASC4KIDS: A multicenter, open-label, phase 1b/2 study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP)

Nobuko Hijiya

  • Presentation # CML-532 – Poster
    Sep 06, 2023 | 06:00 PM - 07:30 PM CT

This presentation will be available once the congress embargo lifts

Matching-adjusted indirect comparisons of asciminib vs other tyrosine kinase inhibitors in third- or later-line chronic myeloid leukemia in chronic phase

Ehab L Atallah

  • Presentation # CML-311 – Poster
    Sep 06, 2023 | 06:00 PM - 07:30 PM CT

This presentation will be available once the congress embargo lifts

ASC4START: A phase 3b, open-label, randomized study of asciminib vs nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase (CML-CP)

Stephen Strickland

  • Presentation # CML-590 – Poster
    Sep 06, 2023 | 06:00 PM - 07:30 PM CT

This presentation will be available once the congress embargo lifts

Responses with asciminib continue to deepen over time in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase 3 ASCEMBL study

Michael J Mauro

  • Presentation # CML-398 – Poster
    Sep 06, 2023 | 06:00 PM - 07:30 PM CT

This presentation will be available once the congress embargo lifts

The Importance of Quality of Survivorship: US Results From the Chronic Myeloid Leukemia (CML) Survey on Unmet Needs (SUN)

Joannie Clements

  • Presentation # CML-562 – Poster
    Sep 06, 2023 | 06:00 PM - 07:30 PM CT

This presentation will be available once the congress embargo lifts

ASC2ESCALATE: A US, phase II, single-arm, dose-escalation study of asciminib monotherapy in second-line and first-line treatment of patients with chronic myeloid leukemia in chronic phase

Ehab L Atallah

  • Presentation # CML-573 – Poster
    Sep 06, 2023 | 06:00 PM - 07:30 PM CT

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound